Orthofix Medical Inc. (NASDAQ:OFIX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $21.75.
OFIX has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Orthofix Medical in a research note on Saturday, September 27th. Barrington Research reissued an “outperform” rating and set a $17.00 target price on shares of Orthofix Medical in a report on Tuesday, September 23rd. JMP Securities restated a “market perform” rating on shares of Orthofix Medical in a research report on Friday, June 6th. Finally, Wall Street Zen upgraded Orthofix Medical from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th.
Get Orthofix Medical alerts:
Read Our Latest Stock Report on OFIX
Orthofix Medical Trading Up 2.8%
NASDAQ:OFIX opened at $14.61 on Wednesday. The stock has a market cap of $576.95 million, a price-to-earnings ratio of -4.61 and a beta of 0.89. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.50 and a current ratio of 2.67. Orthofix Medical has a 1 year low of $10.24 and a 1 year high of $20.73. The business has a fifty day moving average of $13.99 and a 200-day moving average of $13.03.
Orthofix Medical (NASDAQ:OFIX – Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The medical device company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.40). The company had revenue of $203.12 million for the quarter, compared to the consensus estimate of $196.89 million. Orthofix Medical had a negative net margin of 15.29% and a negative return on equity of 25.43%. Orthofix Medical has set its FY 2025 guidance at EPS. Equities analysts predict that Orthofix Medical will post -2.81 earnings per share for the current year.
Institutional Investors Weigh In On Orthofix Medical
Hedge funds and other institutional investors have recently bought and sold shares of the business. US Bancorp DE lifted its holdings in Orthofix Medical by 684.6% in the 1st quarter. US Bancorp DE now owns 5,673 shares of the medical device company’s stock valued at $93,000 after acquiring an additional 4,950 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Orthofix Medical during the second quarter valued at approximately $147,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its holdings in Orthofix Medical by 32.6% during the second quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 13,297 shares of the medical device company’s stock worth $148,000 after buying an additional 3,271 shares in the last quarter. Strs Ohio bought a new stake in Orthofix Medical during the first quarter worth approximately $150,000. Finally, The Manufacturers Life Insurance Company grew its position in Orthofix Medical by 21.1% in the second quarter. The Manufacturers Life Insurance Company now owns 14,867 shares of the medical device company’s stock worth $166,000 after buying an additional 2,589 shares during the last quarter. 89.76% of the stock is currently owned by institutional investors.
About Orthofix Medical
(Get Free Report)
Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.
Recommended Stories
Five stocks we like better than Orthofix Medical
3 Best Fintech Stocks for a Portfolio Boost
After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught?
Investing In Preferred Stock vs. Common Stock
Alphabet: After Its Best Quarter in Decades, Is It Time to Buy?
What is a Secondary Public Offering? What Investors Need to Know
Forget Airlines—These Trucking Stocks Are Shifting Into High Gear
Orthofix Medical Inc. (NASDAQ:OFIX) Receives $21.75 Consensus Price Target from Brokerages
